Cubist Antibiotic Shines In Trials; Stock Jumps
Cubist Pharmaceuticals (CBST) reported positive late-stage trial results for its antibiotic candidate Monday, sending Cubist stock to a 13-year high on the stock market today. The drug, ceftolozane/tazobactam, known in the industry as tol/taz for short, was tested in patients with urinary tract infections and compared to levofloxacin, which is known commercially as Johnson & Johnson’s (JNJ) Levaquin and Sanofi’s (SNY) Tavanic. Cubist said tol/taz